Edition:
United Kingdom

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.50EUR
4:35pm BST
Change (% chg)

€-0.06 (-0.52%)
Prev Close
€11.56
Open
€11.52
Day's High
€11.70
Day's Low
€11.44
Volume
79,527
Avg. Vol
122,465
52-wk High
€12.90
52-wk Low
€9.67

About

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The... (more)

Overall

Beta: --
Market Cap(Mil.): €473.27
Shares Outstanding(Mil.): 44.65
Dividend: --
Yield (%): --

Financials

  BCART.BR Industry Sector
P/E (TTM): -- 32.13 32.55
EPS (TTM): -1.16 -- --
ROI: -48.76 13.70 13.82
ROE: -60.67 16.39 15.24

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

29 Nov 2018

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

29 Nov 2018

Biocartis partners with AstraZeneca on lung cancer diagnostics

Nov 29 Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

29 Nov 2018

Earnings vs. Estimates